The global Pompe disease treatment market is characterized by the presence of many global, regional, and local vendors. This is an emerging market with all the players involved in developing best-in-class products to gain maximum market share. Intense competition, rapid advancement in technology, frequent changes in government policies, and environmental regulations are the key factors that confront the global market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive market environment.
The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on expanding geographic presence and enhancing product quality. Although international players are dominating the market, regional and foreign players with small market shares also hold substantial shares. The international players are likely to increase their presence through acquisitions during the forecast period.
Vendors with better technical and financial resources could develop innovative products. Therefore, vendors must develop new technologies to be alongside the emerging technologies that could affect the continuing competitiveness of their product lines in the global market.
There are various players operating in this market all over the globe. The market is highly consolidated with the presence of different small and big players. Most of these players have a strong presence in the American and European regions. The major players in the global Pompe disease treatment market are Sanofi, CENTOGENE AG, and Amicus Therapeutics, Inc.
Sanofi Genzyme is a specialty care business unit of Sanofi that operates in various rare diseases, multiple sclerosis, immunology, and oncology. The company offers drugs, food supplements, generic medicines, and cosmetics, as well as provides medical devices for cancer, cardiology, gynecology, and diabetes. The company operates in more than 100 countries with industrial sites in 38 countries. The company is headquartered in Cambridge, US, and employs more than 10,000 people and offers products to customers across the globe. High customer satisfaction level, exceptional performance in new markets, and broad brand portfolio add to the company’s competitive advantage within the global Pompe disease treatment market
CENTOGENE AG is a leading genetic biotech company that offers biochemical diagnostic tests, genetic diagnostic tests, next-generation sequencing, and biomarkers used for the diagnosis of rare hereditary disorders. CENTOGENE AG supports clinicians with genetic counseling services, as well as performs analysis of biomarkers for lysosomal storage disorders. The company also provides Extan kits for various genetic diseases, such as Ehlers-Danlos syndrome, Charcot-Marie-Tooth disease, spastic paraplegia, dystonia, osteogenesis imperfecta, and Alpers syndrome. Headquartered in London, UK, it employs more than 500 people and offers products to customers across the globe
Amicus Therapeutics, Inc. is a leading biotech company focused on discovering, developing and delivering high-quality medicines for people with rare metabolic diseases. Moreover, Amicus also has a broad gene therapy collaboration with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania. There are six active preclinical programs in development with the University of Pennsylvania including Pompe disease. Thus, the company’s product portfolio for Pompe disease treatment would help to garner maximum market share in the global Pompe disease treatment market.
Bargaining Power of Suppliers
Bargaining power of suppliers in the Pompe disease treatment market is low to moderate. The number of suppliers in the market is high, which gives plenty of options to drug manufacturers for material sourcing, which is required to produce the various drugs, thus leaving suppliers with medium bargaining power. Another, factor affecting the bargaining power of suppliers is the supplier switching cost for buyers owing to the presence of a moderate number of raw material suppliers in the market. On the other hand, only a moderate number of viable raw material substitutes are available, which further boosts the bargaining power of suppliers in the market. In addition, low chances of forwarding integration decrease the bargaining power of suppliers.
Bargaining Power of Buyers
The bargaining power of buyers is expected to be low in the global Pompe disease treatment market. Several manufacturers are performing extensive R&D to launch innovative products in the market. For instance, Amicus Therapeutics, Inc received two new patents for Pompe enzyme ATB200. These patents provide Amicus with wide and long-term intellectual property rights and significantly strengthen their position for Pompe disease. But the limited number of market players and high buyer concentration lowers the bargaining power of buyers. While demand for Pompe disease treatment is high, supply is extremely limited; moreover, the cost of treatment is high with no direct substitutes available. This lowers the bargaining power of the buyer in the market.
Threat of New Entrants
The global Pompe disease treatment market has high growth potential. Currently, there are limited manufacturers of Pompe disease treatment with a prominent presence, especially in the US and Europe. However, the costs involved in the manufacturing process, as well as the complexity in formulating enzyme replacement therapy drugs makes it difficult for new players to achieve economies of scale, which the existing companies already possess. Moreover, stringent regulations make it difficult for new players to enter the market. Hence, the threat of new entrants in the global Pompe disease treatment market is moderate.
Threat of Substitutes
The threat of substitutes in the global Pompe disease treatment market is low as there is no direct substitute available in the market. For instance, enzyme replacement therapy (ERT) is the only Food and Drug Administration (FDA) approved therapy for the treatment of Pompe disease. Other therapies such as gene therapy and substrate reduction therapies are still in the preclinical stage. However, the effectiveness of ERT makes it a highly sought-after treatment method. Moreover, raising awareness among the public about rare diseases and government initiatives is driving the demand for Pompe disease treatment methods. Therefore, the threat of substitutes in the market is expected to be low.
Intensity of Rivalry
The intensity of rivalry in the Pompe disease treatment market is high. The restrained degree of product differentiation among existing players maintains a high degree of rivalry in the market and a major share of the market is held by the key market players. Manufacturers operating in the Pompe disease treatment market are trying to develop a more efficient and cost-effective treatment to make the product more affordable in the developing regions. To overcome the competition, players are engaged in developing a process which can lower their manufacturing cost. Moreover, the players are also developing advanced and new formulations to differentiate their product from their rivals.
